Tag: precision diagnostic

“Primary-Care Pathology” One Goal at Beth Israel

By Robert Michel, from the Volume XVII No. 15 - October 25, 2010 issue

CEO SUMMARY: In a pioneering collaboration, the pathology department at Beth Israel Deaconess Medical Center in Boston, Massachusetts, will work with GenomeQuest, Inc., to perform whole genome sequencing of tumor specimens. GenomeQuest will handle sequencing, assembly, and annotation of the genetic data. BIDMC will analyze these whole human genome sequences to develop companion diagnostic tests

View Article

Busy Year Demonstrated By Top Ten Lab Stories

By Robert Michel, from the Volume XIV No. 17 - December 10, 2007 issue

CEO SUMMARY: As it turns out, 2007 has been an action-packed year with lots of events, plenty of changes, and the promise of even faster evolution across all sectors of the lab testing marketplace. THE DARK REPORT’S “Top Ten Lab Stories of 2007” show the full intensity and pace of activity within laboratory medicine. One big driver in

View Article

Inverness Buys Biosite, Has New Venture with P&G

By Robert Michel, from the Volume XIV No. 8 - June 4, 2007 issue

CEO SUMMARY: On the same day that Inverness Medical Innovations announced that it would acquire Biosite, thus beating out Beckman Coulter in the bidding war for Biosite, Inverness also announced that it had entered into a joint venture with Procter & Gamble. Together, the two companies will develop, make, and market consumer diagnostics products to

View Article

Procter & Gamble Moves into the Neighborhood

By R. Lewis Dark, from the Volume XIV No. 8 - June 4, 2007 issue

LAST MONTH, A NEW RESIDENT BOUGHT INTO THE LABORATORY TESTING NEIGHBORHOOD. Procter & Gamble Company spent a third of a billion dollars to enter a joint venture with Inverness Medical Products, Inc., with the specific goal of selling diagnostic test kits to consumers in pharmacies, grocery stores, and other retail outlets.

As you will read on

View Article

Volume XXVI No. 2 – February 4, 2019

NOW THAT MOST HOSPITALS ARE INCLUDED as applicable laboratories that must report their PAMA private payer lab test price data to the Centers for Medicare and Medicaid Services, managers of those labs will benefit from the incisive analysis in this issue of the lessons learned during the 2017 PAMA reporting cycle. THE DARK REPORT further offers recommendations on how labs can do a better job of gathering and reporting their own data to CMS. Also, TDR delivers an exclusive analysis of why the Government Accounting Office's assertion that CMS will be paying billions more for Part B clinical lab tests is simply wrong.

See the full table of contents

Tag: precision diagnostic

Enter Your Login Credentials